AlloVir to merge with Kalaris in all-stock deal; Kalaris stockholders to own ~75% of combined company

Kalaris Therapeutics, Inc.

AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.
Combined company expected to have ~$100M cash at close (expected Q1 2025), providing runway into Q4 2026.
Pipeline focuses on TH103 (anti-VEGF fusion protein) for neovascular AMD; Phase 1 data expected Q3 2025; also planned for DME and RVO.
Stockholders owning 87.4% of Kalaris and 29.4% of AlloVir have entered support agreements to vote in favor.
Post-close company to rename Kalaris Therapeutics, trade on Nasdaq under ticker KLRS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.